Clinical use of the calcium-binding S100B protein

Methods in Molecular Biology

Volumn 963, Issue , 2013, Pages 373-384

  Astrand, Ramona ^a   Undén, Johan ^b   Romner, Bertil ^a  

^a Rigshospitalet   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer s disease; Calcium; EF hand; Malignant melanoma; Minor head injury; S100B; Traumatic brain injury

Indexed keywords

PROTEIN S100B; BIOLOGICAL MARKER; CALCIUM; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

BIOCHEMISTRY; BLOOD BRAIN BARRIER; CALCIUM BINDING; CALCIUM HOMEOSTASIS; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; ENZYME ACTIVITY; HEAD INJURY; HUMAN; INJURY SEVERITY; PHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SCHWANN CELL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; BLOOD; DISEASES; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; CALCIUM; DISEASE; HUMANS; NERVE GROWTH FACTORS; S100 PROTEINS;

EID: 84878755537     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-230-8_23     Document Type: Chapter

References (68)

1. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739–744.
2. Isobe T, Okuyama T (1981) The amino-acid sequence of the alpha subunit in bovine brain S-100a protein. Eur J Biochem 116:79–86.
3. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111–1122.
4. Marenholz I, Lovering RC, Heizmann CW (2006) An update of the S100 nomenclature. Biochim Biophys Acta 1763:1282–1283.
5. Kizawa K, Takahara H, Unno M, Heizmann CW (2011) S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie 93:2038–2047.
6. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B et al (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 26:3868–3878.
7. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396:201–214.
8. Donato R, Heizmann CW (2010) S100B protein in the nervous system and cardiovascular apparatus in normal and pathological conditions. Cardiovasc Psychiatry Neurol 2010:929712.
9. Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–518.
10. Haimoto H, Hosoda S, Kato K (1987) Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues. Lab Invest 57:489–498.
11. Wiesmann M, Missler U, Gottmann D, Gehring S (1998) Plasma S-100b protein concentration in healthy adults is age- and sexindependent. Clin Chem 44:1056–1058.
12. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR et al (2003) Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 21:109–121.
13. Jonsson H, Johnsson P, Hoglund P, Alling C, Blomquist S (2000) Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 14:698–701.
14. Blomquist S, Johnsson P, Luhrs C, Malmkvist G, Solem JO, Alling C et al (1997) The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth 11:699–703.
15. Raabe A, Kopetsch O, Gross U, Zimmermann M, Gebhart P (2003) Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin Chem Lab Med 41:700–703.
16. Hallen M, Carlhed R, Karlsson M, Hallgren T, Bergenheim M (2008) A comparison of two different assays for determining S-100B in serum and urine. Clin Chem Lab Med 46:1025–1029.
17. Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932.
18. Kunihara T, Shiiya N, Bin L, Yasuda K (2006) Arterio-jugular differences in serum S-100beta proteins in patients receiving selective cerebral perfusion. Surg Today 36:6–11.
19. Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B et al (2007) S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62:1452–1456.
20. Astrand R, Romner B, Lanke J, Unden J (2011) Reference values for venous and capillary S100B in children. Clin Chim Acta 412:2190–2193.
21. Ingebrigtsen T, Romner B, Kock-Jensen C (2000) Scandinavian guidelines for initial management of minimal, mild, and moderate head injuries. The Scandinavian Neurotrauma Committee. J Trauma 48:760–766.
22. af Geijerstam JL, Britton M (2003) Mild head injury—mortality and complication rate: metaanalysis of findings in a systematic literature review. Acta Neurochir (Wien) 145:843–850, discussion 850.
23. Unden J, Bellner J, Astrand R, Romner B (2005) Serum S100B levels in patients with epidural haematomas. Br J Neurosurg 19:43–45.
24. Unden J, Romner B (2009) A new objective method for CT triage after minor head injury— serum S100B. Scand J Clin Lab Invest 69:13–17.
25. Biberthaler P, Mussack T, Wiedemann E, Gilg T, Soyka M, Koller G et al (2001) Elevated serum levels of S-100B re flect the extent of brain injury in alcohol intoxicated patients after mild head trauma. Shock 16:97–101.
26. Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Koelsch M, Gippner-Steppert C et al (2001) Evaluation of S-100b as a speci fic marker for neuronal damage due to minor head trauma. World J Surg 25:93–97.
27. Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J et al (2000) The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 14:1047–1055.
28. Mussack T, Biberthaler P, Kanz KG, Heckl U, Gruber R, Linsenmaier U et al (2002) Immediate S-100B and neuron-speci fic enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients. Shock 18:395–400.
29. Poli-de-Figueiredo LF, Biberthaler P, Simao Filho C, Hauser C, Mutschler W, Jochum M (2006) Measurement of S-100B for risk classi fication of victims sustaining minor head injury— first pilot study in Brazil. Clinics (Sao Paulo) 61:41–46.
30. Unden J, Romner B (2010) Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidencebased review and meta-analysis. J Head Trauma Rehabil 25:228–240.
31. Kleine TO, Benes L, Zofel P (2003) Studies of the brain speci ficity of S100B and neuronspeci fic enolase (NSE) in blood serum of acute care patients. Brain Res Bull 61:265–279.
32. Unden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B (2005) Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 58:59–61.
33. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48:1255–1258, discussion 1258–1260.
34. Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Gilg T, Gippner-Steppert C et al (2000) In fluence of alcohol exposure on S-100b serum levels. Acta Neurochir Suppl 76:177–179.
35. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG et al (2006) Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 25:446–453.
36. Zongo D, Ribereau-Gayon R, Masson F, Laborey M, Contrand B, Salmi LR et al (2011) S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 59:209–218.
37. Raabe A, Grolms C, Seifert V (1999) Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg 13:56–59.
38. Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B et al (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91.
39. da Rocha AB, Schneider RF, de Freitas GR, Andre C, Grivicich I, Zanoni C et al (2006) Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 44:1234–1242.
40. Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U (2010) Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 121:178–185.
41. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T et al (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793.
42. Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483.
43. Woertgen C, Rothoerl RD, Metz C, Brawanski A (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130.
44. Nylen K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K et al (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 150:221–227, discussion 227.
45. Bohmer AE, Oses JP, Schmidt AP, Peron CS, Krebs CL, Oppitz PP et al (2011) Neuronspeci fic enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 68:1624–1631.
46. Dimopoulou I, Kor fias S, Dafni U, Anthi A, Psachoulia C, Jullien G et al (2003) Protein S-100b serum levels in trauma-induced brain death. Neurology 60:947–951.
47. Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M et al (2011) Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien) 153:90–100.
48. Unden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P et al (2007) Clinical signi ficance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99.
49. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO (2009) S-100B and neuron speci fic enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 80:1241–1247.
50. Pelinka LE, Toegel E, Mauritz W, Redl H (2003) Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 19:195–200.
51. Bechtel K, Frasure S, Marshall C, Dziura J, Simpson C (2009) Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics 124:e697–e704.
52. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM (2005) Serum neuron-speci fic enolase, S100B, and myelin basic protein concentrations after in flicted and nonin flicted traumatic brain injury in children. J Neurosurg 103:61–68.
53. Castellani C, Bimbashi P, Ruttenstock E, Sacherer P, Stojakovic T, Weinberg AM (2009) Neuroprotein s-100B—a useful parameter in paediatric patients with mild traumatic brain injury? Acta Paediatr 98:1607–1612.
54. Castellani C, Stojakovic T, Cichocki M, Scharnagl H, Erwa W, Gutmann A et al (2008) Reference ranges for neuroprotein S-100B: from infants to adolescents. Clin Chem Lab Med 46:1296–1299.
55. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E et al (1999) S100B protein detection in serum is a signi ficant prognostic factor in metastatic melanoma. Oncology 56:338–344.
56. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E et al (1999) Prognostic signi ficance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155–161.
57. Molina R, Navarro J, Filella X, Castel T, Ballesta AM (2002) S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23:39–44.
58. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G et al (2003) Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease. Neurosci Lett 336:167–170.
59. Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614–632.
60. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuronspeci fic enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia– original research and meta-analysis. Psychiatry Res 167:66–72.
61. Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB (2010) Systemic markers of in flammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 7:71.
62. Peskind ER, Grif fin WS, Akama KT, Raskind MA, Van Eldik LJ (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease. Neurochem Int 39:409–413.
63. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall’Igna O et al (2010) Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 7:6.
64. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K et al (2007) Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 186:181–192.
65. Mitosek-Szewczyk K, Gordon-Krajcer W, Flis D, Stelmasiak Z (2011) Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse. Folia Neuropathol 49:191–196.
66. Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: an update. Gen Physiol Biophys 28 Spec No Focus:F76–F81.
67. Muller K, Elverland A, Romner B, Waterloo K, Langbakk B, Unden J et al (2006) Analysis of protein S-100B in serum: a methodological study. Clin Chem Lab Med 44:1111–1114.
68. Alber B, Hein R, Garbe C, Caroli U, Luppa PB (2005) Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 43:557–563.